Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Jennifer Levin (email | Twitter) and we will feature it...
The well-armed German pricing gatekeepers have dismissed two more Big Pharma drugs. Pfizer's ($PFE) lung cancer treatment Xalkori and the Bristol-Myers Squibb ($BMY)/AstraZeneca ($AZN) diabetes drug Komboglyze both got an initial thumbs-down from the Institute for Quality and Efficiency in Health Care (IQWiG).
From a strictly numbers point of view, last year's results are pretty obvious. As the accompanying chart indicates, 2012 was the slowest in 5 years in terms of both number of deals and dollars on the table. To Christian Dokomajilar, manager and senior biotech analyst at Deloitte Recap, that actually bodes well for 2013. Read the report >>
A U.S. court has struck Baraclude from the patent list. The Bristol-Myers Squibb ($BMY) hepatitis B drug saw its composition of matter patent invalidated in a court fight with Teva Pharmaceutical Industries ($TEVA), which wants to sell its own version.
Reckitt Benckiser has nabbed Latin American rights to a basket of Bristol-Myers Squibb's ($BMY) over-the-counter products for a cool $482 million.
It would be difficult to miss the major trend in Big Pharma's latest round of earnings reports: Flat sales, falling profits, generic erosion and lots of talk about near-term growth from newly approved and forthcoming products.
Two consumer health deals, two Big Pharma approaches toward emerging markets. While Bristol-Myers Squibb is looking around for buyers for a portfolio of consumer brands in Latin America, GlaxoSmithKline has staked another $900 million on the consumer health market in India.
AstraZeneca's new chief executive, Pascal Soriot wants the diabetes marketing teams from the AstraZeneca and Bristol-Myers Squibb partnership to think deep thoughts about how they are going to sell more products. To do that, they have been put together and the team then sequestered in their own home away from the distractions of their respective companies.
Forxiga, approved in November for sale in the EU, failed to impress the gatekeepers at the National Institute for Health and Clinical Excellence. Essentially, NICE isn't yet convinced that Forxiga works any better as an add-on therapy than other drugs already in use.
Three years after Bristol-Myers Squibb and Eli Lilly settled a nasty legal scrap over the rights to necitumumab--a cancer drug initially pursued by ImClone and pushed ahead into late-stage tests--BMS has dumped its rights to the troubled program.